The number of patients in buprenorphine opioid substitution therapy (BOST) or methadone opioid substitution therapy (MOST) programs is increasing. If these patients require surgery, it is generally agreed that methadone should be continued perioperatively. while some also recommend that buprenorphine is continued, concerns that it may limit the analgesic effectiveness of full mu-opioid agonists have led others to suggest that it should cease before surgery.
According to the Australian Institute of Health and Welfare's National Drug Strategy Household Survey 1 , the number of Australians ≥14 years with self-reported heroin use in the 12 months prior to each survey date (these surveys are conducted every two to three years) has remained stable from 2001-2010 at 0.2% of the population. The proportion that reportedly used prescription opioids for non-medical purposes over this time has increased from 0.3 to 0.4%.
However, over a similar period from 2001 to 2011, the total number of Australians receiving pharmaco-therapy (opioid substitution therapy [OST]) using methadone or buprenorphine for treatment of their addiction to opioids has increased from 32,516 to 46,446. In 2011, 68% of those in OST programs were 30-49 years and 65% were male; 69% were prescribed methadone and the remainder either buprenorphine alone (Subutex ® , Reckitt Benkiser Healthcare Ltd, UK) or a buprenorphine-naloxone combination (Suboxone ® , Reckitt Benkiser Healthcare Ltd, UK) 2 .
Effective postoperative pain management in patients who are in methadone opioid substitution therapy (MOST) or buprenorphine opioid substitution therapy (BOST) programs may, as with other patients taking long-term opioids, present greater challenges than in patients who are opioid-naive, in part due to development of opioid tolerance and hyperalgesia, physical dependence and any associated behavioural, psychiatric or social issues.
It is generally agreed that if a patient uses a longacting opioid on a daily basis, the usual full agonist opioid (e.g. methadone, morphine) or equivalent should be continued during the perioperative period [3] [4] [5] [6] [7] but advice regarding buprenorphine has varied. Concerns that buprenorphine's long half-life, high opioid receptor affinity, partial agonist activity and slow dissociation from the mu-receptor, may reduce the analgesic effectiveness of full mu-opioid agonists 8, 9 have led to conflicting recommendations about its continuation or otherwise around the time of surgery.
Some authors have recommended that buprenorphine should be continued throughout the perioperative period [4] [5] [6] [7] . Others have suggested that a change be made from buprenorphine to another opioid (e.g. methadone) a few days before surgeryat least in hospitalised patients and those undergoing surgery likely to result in moderate to severe pain 9, 10 . Alford et al 10 outlined four possible courses of action, recommending continuation of buprenorphine only if the acute pain is likely to be short in duration; if the patient is hospitalised, conversion to methadone is suggested. An earlier review recommended that buprenorphine be continued where possible, even in patients scheduled for major surgery, but that there was the alternative option of changing the patient to methadone 72 hours preoperatively 8 .
Good evidence for either course of action does not exist. Only a small number of case reports have been published with conflicting conclusions 11, 12 .
In view of the paucity of information regarding acute pain management in BOST patients and the likelihood that the number of BOST patients presenting for management will increase (in part because legislation in some jurisdictions and countries places fewer restrictions on the prescription of Suboxone compared with methadone for patients in OST programs 13 ), better information about analgesic outcomes in BOST patients was needed.
Therefore we performed a retrospective cohort study to compare pain relief and opioid requirements in the first 24 hours after surgery in BOST and MOST patients, using information from our tertiary hospital acute pain service (APS) database and hospital records.
METHODS
Data collected by the APS on MOST and BOST patients undergoing surgery for the five years from January 2005 were examined in this study, which was approved by the hospital Research Ethics Committee (approval number 090320).
Patients were included in the analysis if they required intravenous (Iv) patient-controlled analgesia (PCA) without concurrent continuous regional or epidural analgesia, or local anaesthetic wound infusions. PCA was managed according to our hospital's APS guidelines for the management of acute pain in opioid-tolerant patients, which includes using initial PCA bolus doses that are higher than those prescribed for opioid-naive patients, with subsequent dose adjustments made in an effort to titrate PCA to effect for each patient.
Information from the APS database, collected daily while the patient was under the care of the APS, was supplemented with material from the patient's case notes in order to acquire other relevant medical and drug histories. Data obtained included: patient age and gender; preoperative benzodiazepine, alcohol and cannabis use; presence of psychiatric comorbidities; preoperative buprenorphine and methadone doses; type and duration of surgery; intraoperative opioids and analgesic adjuvants used; and first 24hour postoperative PCA opioid doses, pain scores, presence of nausea, vomiting and pruritus, adjuvant analgesic agents administered, and sedation scores (using a four point scale where 0=none, awake, 1=easy to rouse, 2=easy to rouse but unable to stay awake, and 3=difficult to rouse). Sedation scores are known to be a more reliable clinical indicator of early respiratory depression than a decrease in respiratory rate 14 and our APS guidelines mandate a reduction in the PCA bolus dose in any patient reported to have a sedation score of 2 or more.
To enable comparisons to be made, all intraoperative and postoperative fentanyl doses were converted to morphine equivalent (ME) doses using 10 mg Iv morphine equals 200 µg Iv fentanyl, a conversion ratio we have used in our clinical practice since 1989 5 .
Statistical analysis
Results are presented as patient numbers, percentages or mean ± standard deviation. Statistical comparisons were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC, USA). Continuous outcomes were compared between groups using linear regression models, while binary outcomes were compared using log binomial regression models.
RESULTS

Patient details
Data from 51 patients were collected. Twentynine (57%) were taking MOST and 22 (43%) BOST. Demographic and other patient details are summarised in Table 1 . Patients in both groups were of similar age, but there was a higher proportion of male patients on BOST. Benzodiazepine use was high in both groups of patients, but it was not possible to verify with any certainty whether these had been prescribed or were being taken illicitly. Thirteen MOST and six BOST patients were known to be taking benzodiazepines preoperatively and these were continued after surgery in all but one patient in each group. Almost two-thirds of patients in each group had been diagnosed with depression, anxiety or other psychiatric disorders, including three in each group with schizophrenia.
Duration of surgery was similar in both groups. In general, the mean total intraoperative ME doses administered were relatively small, given that these patients were opioid-tolerant. In 21 of the 51 patients, the ME dose was 25 mg or less; one patient was given just 2.5 mg and the doses ranged from 2.5-250 mg. Of the 51 patients, 12 were given intraoperative ketamine (doses ranging from 10-200 mg) and six received clonidine (doses ranged from 30-165 mg). One patient in the BOST group was given intraoperative remifentanil. Intraoperatively, no patient included in this study was given any spinal or epidural anaesthetic or analgesic medications and no 'single shot' regional or local anaesthetic blocks were performed. No patient was given a gabanoid before surgery or within the first 24 hours after surgery.
BOST and MOST doses and administration
The average doses of buprenorphine and methadone that patients were taking before their surgery are listed in Table 2 . The practice of the APS is to confirm such doses before prescribing these drugs in hospital. while the APS guidelines that were current during the study period recommended that both methadone and buprenorphine be given on the day of surgery as well as continued after surgery, this did not occur in a number of patients in both groups; no reason was recorded in the patients' files. Of those who were not given their OST the first day after surgery, most also missed out on their usual dose on the day of surgery, with only one of the seven MOST and three of the 11 BOST patients taking their preoperative doses.
First 24-hour analgesic doses, efficacy and adverse effects
Information about analgesic use in the first 24 hours after surgery is summarised in Table 3 . The data are grouped to allow a comparison of all BOST and MOST patients, as well as separate comparisons of those patients who were given OST on the first day after surgery with those who were not. There was BOST=buprenorphine opioid substitution therapy, MOST=methadone opioid substitution therapy, SD=standard deviation. no statistically significant correlation between first 24-hour PCA opioid requirement and preoperative BOST or MOST doses in any patient group. All patients received regular paracetamol, while variable numbers were given a non-steroidal antiinflammatory drug or continuous ketamine infusion (4-8 mg/hour). Tramadol was also given to 17.2 and 13.6% of BOST and MOST patients, respectivelytwo MOST and two BOST patients who received OST on the day of surgery and three MOST and one BOST patients who did not.
The number of days that PCA was continued as well as the number of days the patients remained under the care of the APS is also given. It appears that the patients who were not given OST on the day after surgery required PCA for longer than other patients and they also required a longer period of supervision by the APS.
Mean PCA ME doses were high in both patient groups (Figure 1 ). There was no significant difference in ME requirements between BOST and MOST patients overall, or in patients who did or did not receive MOST on the first day after surgery. However, BOST patients who were not given buprenorphine the day after surgery had significantly higher (P=0.02) PCA ME requirements in the first 24 hours after surgery, compared with those who were given their usual dose.
Pain scores and the incidence of adverse effects are summarised in Table 4 . There were no significant differences between pain scores at rest and movement on the first day after surgery in BOST compared with MOST patients, or within each group depending on whether the patient had been given OST on the day after surgery. There were also no significant differences between the incidence of nausea and vomiting for which antiemetics were required or the number of patients with a sedation score of 2. * Given or not given on the first day after surgery. † The mean PCA morphine equivalent dose was significantly higher (P=0.02) in patients who did not receive buprenorphine the first day after surgery compared with those who did receive buprenorphine. BOST=buprenorphine opioid substitution therapy, MOST=methadone opioid substitution therapy, PCA=patient-controlled analgesia, SD=standard deviation, NSAID=non-steroidal anti-inflammatory drugs, APS=acute pain service. 
DISCUSSION
we have shown that there was no difference between BOST and MOST patients in either the efficacy or side-effect profile of PCA opioids prescribed to relieve postoperative pain relief in BOST or MOST patients. As expected, PCA ME doses were higher than those seen in the average postsurgical opioidnaive population 15 but similar in the BOST and MOST groups overall. The only significant difference found was that patients who were not given their usual BOST on the first day after surgery, most of whom (eight out of 11 patients) also did not receive their usual dose the morning of their operation, had higher PCA ME requirements than those who continued BOST.
Our choice of the Iv morphine to fentanyl conversion ratio of 10 mg morphine equals 200 µg fentanyl was based on our clinical practice, starting in 1989, of using these as equivalent bolus doses when prescribing PCA. It is supported by the most recent addition of Analgesic Therapeutic Guidelines 16 which states that 150-200 µg of fentanyl and 10 mg morphine are equianalgesic Iv doses. This could be criticised because of the lack of evidence underpinning such a choice. Unfortunately, there are few data to support any fixed conversion ratios 17 , including the commonly quoted 10 mg Iv morphine equals 100 µg fentanyl, especially when repeated dosing in either acute and chronic care situations is used. The estimates of relative potencies listed in published equianalgesic dose tables have commonly been derived from older often single-dose studies and used with little modification for a number of decades 17, 18 .
The Australian Medicines Handbook 19 lists the range 100-150 µg Iv fentanyl as the equivalent of 10 mg Iv morphine. For transdermal fentanyl patches, that is continuous dosing equivalent to Iv doses, it is said that "the 12 micrograms/hour patch is approximately equivalent to 45 mg/day oral morphine" 19 . Over a 24-hour period this would mean that 288 µg fentanyl is equivalent to 45 mg oral morphine or 15 mg Iv morphine, or that 10 mg Iv morphine equals 192 µg Iv fentanyl.
So the 200 µg conversion we used seems appropriate. However, for completeness and to assess the effects on our results, we repeated the same calculations using the lower conversion dose of 150 µg fentanyl. First 24-hour PCA ME requirements for all BOST patients, those given BOST on the day after surgery, those not given BOST, all MOST patients, those given MOST on the day after surgery and those not given MOST were a little higher in all but the last group of patients who did not receive MOST. There was still no difference in PCA ME requirements between BOST and MOST patients overall and the only significant difference (P=0.03) was, again, that patients who were not given their usual BOST on the first day after surgery had higher PCA opioid requirements (PCA ME=307.0±154.2) than those who continued BOST (PCA ME=198.2±182.6).
Buprenorphine is usually described as a partial mu-agonist and kappa-antagonist 6, 20 . A recent review concluded that, at clinically effective analgesic doses (the authors did not consider the higher doses commonly used in BOST), it behaves as a full muopioid agonist-that is that there is no evidence of a 'ceiling effect' in humans for pain relief 20 . The results of our study suggest that PCA opioid requirements will be lower if BOST is continued after surgery, implying, perhaps, that even at higher doses, buprenorphine may still have some analgesic effect.
Positron emission tomographic scan studies have shown that at buprenorphine maintenance doses of 16 and 32 mg (administered as sublingual tablets), whole brain mu-opioid receptor availability is reduced by 80 and 84%, respectively, whereas the reduction is only 41% with the 2 mg dose 21 . As such, concerns about the ability of higher doses of buprenorphine to limit access of full mu-opioid agonists to opioid receptors and therefore reduce their analgesic effectiveness would seem reasonable 8, 9 . However, our study suggests that such concerns are unwarranted. The continued administration of buprenorphine in the high doses used in BOST resulted in lower first 24-hour postoperative PCA opioid requirements compared with PCA requirements when buprenorphine was withheld. Thus while position emission tomographic imaging studies show that opioid receptor occupancy is high for buprenorphine in the dose range received by our patients, our data do not support the commonly held belief that this will interfere with the activity of additional full agonist opioids given for the relief of postoperative pain. while the differences in PCA requirements between patients who did and did not receive MOST were not significant, the results showed a similar trend. This suggests that the perioperative management of patients taking BOST or MOST can be similar and that MOST patients will also benefit from being given their usual dose of methadone.
Our results relating to PCA efficacy and safety are in keeping with another study which compared first 24-hour PCA opioid requirements, pain scores and adverse effects in opioid-tolerant and opioid-naive patients after a variety of surgical procedures 22 . The opioid-tolerant group, a mix of patients with cancer pain, chronic non-cancer pain and those with an addiction to opioids, required approximately three times the amount of PCA opioid: the average first 24hour morphine-equivalent dose was 135.8±68.5 mg compared with 42.8±32.0 mg in their opioid-naive counterparts 22 . These doses were lower than the PCA requirements of the BOST and MOST patients in our study. Rapp et al 22 also found that their opioidtolerant patients, who remained under the care of the APS longer than other patients, reported higher pain scores at rest and with movement.
There are only a few case reports describing experiences with acute pain management in BOST patients. In one young patient with multiple injuries (including hepatic and splenic lacerations, closed head injury and fractured ribs), adequate analgesia in the early stages of admission was not obtained until after his Suboxone was ceased 11 . However, the analgesic regimen was complicated by his closed head injury, persistent agitation and other medications required. Hence, it is difficult to generalise about acute pain management in BOST patients from this case.
In contrast, the authors of a case series which included five patients who underwent seven major operations while maintained on their usual dose of buprenorphine (2-24 mg/day), reported that good postoperative analgesia was able to be obtained using full agonist opioids 12 . However, unlike the patients in our study, epidural analgesia (four occasions) and wound infusions of local anaesthetic (two occasions) were used in addition to systemic opioid agonists.
Tolerance to the sedative and emetic effects of opioids taken on an ongoing basis develops reasonably quickly 6 and so it is often assumed that the risk of oversedation/respiratory depression will be less in opioid-tolerant patients. Using a very similar sedation scoring system to ours, Rapp et al 22 reported that the incidence of excessive sedation (sedation scores of 2 and 3) was actually significantly higher in opioidtolerant patients compared with those who were opioid-naive. while this seems counterintuitive, the results of our study were similar. In our institution, just under 1.7% of all patients prescribed with PCA opioids have a sedation score of 2 on the first day after PCA is commenced (unpublished information from our APS database) and yet 22.7 and 24.1% of BOST and MOST patients, respectively, had a sedation score of 2 recorded at some stage during the first 24 hours after their operation. No patient had a sedation score of 3, which would have indicated severe respiratory depression.
Why opioid-tolerant patients should be at increased risk of moderate sedation when using PCA opioids to treat postoperative pain is not clear. It could be that a sudden and marked increase in opioid use somehow overcomes the 'protective' effects of tolerance. yet that would not explain why the incidence of postoperative nausea and vomiting is less in these patients 22 . It could also be that patients who have previously experienced the sedative and euphoric effects of opioid are titrating themselves to a level at which they are able to experience some of the effects of PCA opioids. In the study by Rapp et al 22 a significantly higher number of opioid-tolerant patients were given a benzodiazepine (for anxiolysis), but there was no statistical association found between oversedation and administration of sedative agents. In our study, only the patient's usual benzodiazepines were prescribed. Of the 16 patients in total who were reported to have a sedation score of 2, only three were patients who had been given their usual benzodiazepine medication.
There are many limitations to our uncontrolled cohort study. The patient groups were very heterogeneous and total patient numbers in each group were small. The efficacy and safety of postoperative analgesia in the first 24 hours after surgery was only examined with comparisons made between the two patient groups as a whole (patients prescribed BOST and MOST) and, within each group, between patients who had and had not been given OST on the day after surgery. Most, but not all, patients who did not receive OST on the day after surgery also failed to take OST on the day of surgery. However, further assessment based on this division was not thought warranted as the patient numbers would have been even smaller.
while buprenorphine and methadone doses were confirmed with the prescriber or dispensing pharmacy before prescription and administration in hospital, there was no ability to confirm the type and quantity of any illicit opioid the patient might also be taking. This could affect postoperative opioid requirements, as could the use of cannabis 6 .
Many more BOST than MOST patients were prescribed PCA fentanyl than PCA morphine. This probably simply reflects the increasing trend in our institution over recent years to use fentanyl rather than morphine PCA, and the fact that the greater proportion of BOST patients were seen in the latter years.
There was also no good record of total ketamine dose given as the nursing staff were allowed to vary the infusion rate between 4-8 mg/hour but were not required to keep a record of total cumulative doses. Ketamine is known to improve pain relief and reduce opioid requirements in opioid-tolerant patients 23, 24 and is recommended for use in the management of acute pain in this patient population 6, 7 . Not all patients in this study were prescribed ketamine, which could also have affected the results, although the percentage of patients in the BOST and MOST groups receiving postoperative ketamine overall were similar.
while paracetamol was given to all patients, nonsteroidal anti-inflammatory drugs were not. These are opioid-sparing in opioid-naive patients, but their effect in opioid-tolerant patients has not been studied 7 . with the high PCA dose requirements and large interpatient variability seen in this study, any significant opioid-sparing effect was thought to be unlikely.
The number of patients prescribed BOST may increase in the future. The better safety profile of buprenorphine [25] [26] [27] has meant that, in some countries at least, prescriptions for Suboxone are less tightly regulated than prescriptions for MOST and can be managed by any medical practitioner, after relatively simple certification, in an office setting 25, 26 . Although retention rates in OST programs are perhaps a little higher in patients prescribed MOST, for those who remain in the programs there appears to be no difference in suppression of opioid use 28, 29 .
In Australia, the significant shortfall in the number of OST prescribers available in each state has been known for some time 30 . Legislative changes may be made in order to help with this demand. For example, in South Australia, a policy change came into effect in April 2011 that allows any general practitioner to prescribe Suboxone (buprenorphine/naloxone) for up to five patients with an addiction to opioids, without the need for further accreditation, while MOST patients must remain under the care of an accredited methadone prescriber 13 . Similar changes in the USA, which allow office-based prescribing by physicians who are not addiction medicine specialists, have also improved access to BOST 31 .
These changes in prescribing practices will increase the availability of BOST and therefore the proportion of patients presenting with acute pain who are taking high doses of buprenorphine may increase. The knowledge that there appears to be no clinically significant difference in the efficacy and safety of acute pain management using full agonist opioids compared with use in MOST patients, and that PCA opioid requirements are likely to be lower and not higher when BOST is continued perioperatively, is therefore useful.
The other advantage of not ceasing buprenorphine is that it does not have to be restarted. Advice given for the management of patients transferring from MOST to BOST is usually that the methadone must be ceased for at least 36 hours and the patient should be experiencing mild withdrawal symptoms before buprenorphine is commenced 31 . Similar recommendations have also been given for reinstitution of buprenorphine after surgery when a full agonist opioid has been used for postoperative analgesia 9,10 , "otherwise, the reinitiation of buprenorphine can lead to the rapid onset of intense withdrawal symptoms" 9 .
However, a postoperative patient experiencing withdrawal symptoms is also likely to experience increasing pain. In practice, reintroduction starting at low doses (e.g. 4 mg buprenorphine) and increasing to the patient's usual maintenance dose over a few days can be achieved without any need to cease or reduce the dose of a full agonist opioid and without any obvious signs or symptoms of withdrawal (unpublished observations). There would be no need to do this if the buprenorphine was not stopped in the first instance.
For further information on management of acute pain in opioid patients in general, including those with an addiction to opioids, see Huxtable et al 7 .
In summary, this audit shows that the efficacy and safety of PCA opioids prescribed for the management of postoperative pain is similar for BOST and MOST patients. Importantly, PCA opioid requirements were less in patients in whom BOST was continued perioperatively compared with those patients whose regular BOST was ceased, and therefore BOST should not be withheld in patients undergoing surgery. That is, administration of buprenorphine in BOST patients does not adversely affect acute pain management using full agonist opioids after surgery. Instead it reduces the amount of PCA opioid required in order to achieve the same degree of pain relief.
